Haiyun Liu

Title: Innovations of Haiyun Liu in Monoclonal Antibody Development.

Introduction

Haiyun Liu is a notable inventor based in Jiangsu, China. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work focuses on creating innovative solutions for treating various solid tumors.

Latest Patents

Haiyun Liu holds a patent for a monoclonal antibody designed to antagonize and inhibit the binding of vascular endothelial growth factor (VEGF) to its receptor. This invention includes a mouse monoclonal antibody that targets VEGF and its receptor, along with the amino acid sequences for the heavy chain and light chain variable regions. The patent also outlines a humanized preparation process for the antibody, which can be utilized in pharmaceutical compositions. This humanized antibody or its derivatives can be administered alone or in combination with chemotherapy drugs, providing a broad-spectrum treatment for solid tumors such as colon cancer, breast cancer, and rhabdomyosarcoma.

Career Highlights

Haiyun Liu is currently associated with Suzhou Stainwei Biotech Inc., where he continues to advance his research and development efforts. His innovative work has positioned him as a key figure in the biotechnology sector.

Collaborations

Haiyun Liu collaborates with esteemed colleagues, including Shiping Luo and Hongqun Hu, who contribute to his research endeavors. Their combined expertise enhances the potential impact of their work in the field.

Conclusion

Haiyun Liu's contributions to monoclonal antibody development represent a significant advancement in cancer treatment. His innovative approaches and collaborations continue to pave the way for future breakthroughs in biotechnology.